Changes of serum thymidine kinase in children with acute leukemia

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1925-1928

  Votava, Tomas ^a   Topolcan, Ondrej ^a   Holubec Jr , Lubos ^a,b   Cerna, Zdenka ^a   Sasek, Lumir ^a   Finek, Jindrich ^a   Kormunda, Stanislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Childhood leukemia; Thymidine kinase; Tumour markers

Indexed keywords

FERRITIN; THYMIDINE KINASE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SCREENING; CANCER STAGING; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INFANT; MALE; PRIORITY JOURNAL;

ACUTE DISEASE; ADOLESCENT; BLOOD SEDIMENTATION; CHILD; CHILD, PRESCHOOL; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; INFANT; LEUKEMIA; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 34250728453     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Kralovanszky J, Koves I, Orosz Z, Katona C, Toth K, Rahoty P, Czegledi F, Kovacs T, Budai B, Hullan L and Jeney A: Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors. Oncology 62(2): 167-174, 2002.
2. Wu J, Mao Y, He L, Wang N, Wu C, He Q and Skoq S: A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma. Anticancer Res 20(6C): 4815-4820, 2000.
3. Hannigan BM, Barnet YA, Armstrong DB, McKelvey-Martin VJ and McKenna PG: Thymidine kinases: the enzymes and their clinical usefulness. Cancer Biother 8: 189-197, 1993.
4. Sherley JL and Kelly TJ: Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263: 8350-8358, 1988.
5. Sadamori N: Clinical and biological significance of serum tumor markers in adult T-cell leukemia. Leuk Lymphoma 22(5-6): 415-419, 1996.
6. He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE and Skog S: Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res 26(6C): 4753-4760, 2006.
7. Li HX, Zhang S, Lei DS, Wang XQ, Skog S and He Q: Serum thymidine kinase 1 (S-TK1) is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep 13: 145-149, 2005.
8. Zhang J, Jia Q, Zou S, Zhang P, Zhang X, Skog S, Luo P, Zhang W and He Q: Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 15(2): 455-461, 2006.
9. Zhang F, Pendleton AR, Robinson JG, Monson KO, Murray BK and O'Neill KL: Thymidine kinase 1 immunoassay: potential marker for breast cancer. Cancer Detect Prev 25(1): 8-15, 2001.
10. O'Neill KL, Buckwalter MR and Murray BK: Thymidine kinase: diagnostic and prognostic potential. Expert Rev Mol Dian 1(4): 428-433, 2001.
11. Musto P, Bodenizza C, Falcone A, D'Arena G, Scalzulli P, Perla G, Modoni S, Parlatore L, Balvani MR and Carotenuto M: Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia. Br J Haematol 90(1): 125-130, 1995.
12. O'Neill KL, Zhang F, Li H, Fuja DG and Murray BK: Thymidine kinase 1 - a prognostic and diagnostic indicator in ALL and AML patients. Leukemia 21(3): 560-563, 2007.
13. He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, Fornander T and Skog S: Concentration of thymidine kinase 1 in serum (S-TK1) is more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep 14(4): 1013-1019, 2005.
14. Gronowitz JS, Kallander FR, Diderholm H, Hagberg H and Petterssion U: Application of an in vivo assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 15: 5-12, 1984.
15. Gronowitz JS, Hagberg H, Kallander FR and Simonsson B: The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 47: 487-495, 1983.
16. Hallek M, Wanders L, Strohmeyer S and Emmerich B: Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and broad range of potential clinical applications. Ann Hematol 65: 1-5, 1995.
17. Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I, Thiel E and Emmerich B: Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, non-smoldering chronic lymphoblastic leukemia. Blood 93: 1732-1737, 1999.
18. Di Raimondo F, Giustolisi R, Lerner S, Cacciola E, O'Brien S, Kantarjian H and Keating MJ: Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol 12(5): 621-625, 2001.
19. Poley S, Stieber P, Nussler V, Pahl H and Fateh-Moghadam A: Serum thymidine kinase in non-Hodgkin's lymphomas with special regard to multiple myeloma. Anticancer Res 17(4B): 3025-3029, 1997.
20. Kok M, Bonfrer JM, Korse CM, de Jong D and Kersten MJ Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. Tumor Biol 24(1): 53-60, 2003.
21. European Group on Tumor Markers: Consensus Recommenda-tions. Anticancer Res 19: 2785-2820, 1999.